Ever since monetizing its stake in multiple sclerosis drug Tysabri, Elan Pharmaceuticals has been at the center of attention. It is seemingly reinventing its business on the fly by making a flurry of deals in the past few days while at the same time being doggedly pursued by Royalty Pharma.
In this video, health-care analyst David Williamson discusses Elan's recent wheeling and dealing and whether it is in the best interests of investors.
David Williamson and The Motley Fool have no position in any stocks mentioned. Follow David on Twitter @MotleyDavid. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.